<DOC>
	<DOCNO>NCT02226549</DOCNO>
	<brief_summary>This study evaluate antiviral efficacy , safety , tolerability combination therapy ledipasvir/sofosbuvir ( LDV/SOF ) fixed-dose combination ( FDC ) + vedroprevir ( VDV ) ± ribavirin ( RBV ) 8 week treatment-experienced adult chronic genotype 1 hepatitis C virus ( HCV ) infection cirrhosis .</brief_summary>
	<brief_title>Ledipasvir/Sofosbuvir Fixed-Dose Combination Vedroprevir With Without Ribavirin Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>Age ≥ 18 year , chronic HCV genotype 1 infection Documentation treatmentexperienced receive pegylated interferon ( PegIFN ) + RBV ≥ 4 week duration without additional agent regimen without achieve sustained viral response ( SVR ) Presence compensate cirrhosis Screening laboratory value within defined threshold Must use specific contraceptive method female childbearing potential sexually active male Not pregnant nurse female Coinfection HIV hepatitis B virus ( HBV ) Current prior history clinical hepatic decompensation Chronic use systemic immunosuppressive agent History clinically significant illness medical disorder may interfere subject treatment , assessment compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>hepatitis C</keyword>
	<keyword>Gilead</keyword>
	<keyword>GS-9451</keyword>
</DOC>